Compare GSK plc (GSK) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Matson Inc — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Matson Inc trades at $224.59 (market cap $6.32B). The key difference: GSK plc is far larger — about 16× Matson Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MATX | |
|---|---|---|
Market Cap | $101.34B | $6.32B |
Sector | Health | Technology |
52-Week High | $61.18 | $210.95 |
52-Week Low | $36.20 | $88.05 |
Enterprise Value | $121.95B | $6.92B |
Dividend Yield | 3.49% | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Matson (MATX) trades at $226.01, up 7.14% over 24 hours, with bullish technical signals from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.85, exceeding expectations, and announced a dividend increase to $0.38 per share. Valuation metrics show a P/E of 15.5 and ROE of 16%, reflecting solid profitability. Preliminary Q2 2026 results indicate continued strength in China service operations.
Outlook remains positive due to consistent earnings outperformance and strategic fleet renewal, but risks include exposure to trade volatility and competitive pressures. Analyst consensus is bullish with 64% buy ratings, supporting potential upside if operational trends persist amid global economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
